20:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

BM32: Ph IIb data

Top-line data from 124 evaluable grass pollen-allergic patients in a double-blind, Austrian Phase IIb trial showed that once-monthly 80 µg subcutaneous BM32 for 5 months was superior to the 3- and 4-month dose regimens of...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

BM32: Phase IIb data

Data from 141 evaluable patients with grass pollen allergy in a double-blind, European Phase IIb trial showed that subcutaneous BM32 improved the mean daily combined symptom and medication score, the primary endpoint, by 22% vs....
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

BM32: Phase IIb ongoing

Biomay said an independent DMC recommended continuation of a double-blind, placebo-controlled, European Phase IIb trial of BM32 into the next treatment year based on a review of symptom medication score and safety data from the...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

BM32: Phase IIa data

Top-line data from a double-blind, placebo-controlled, Austrian Phase IIa trial in 70 patients with grass pollen allergy showed that 3 injections of once-monthly subcutaneous BM32 significantly reduced nasal allergy symptoms induced by a grass pollen...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

rBet v 1: Phase IIb/III data

The double-blind, international Phase IIb/III VO59.08 trial in 483 adult patients showed that 12.5, 25 and 50 µg sublingual tablets of rBet v 1 met the primary endpoint of significantly reducing AASS vs. placebo (0.002
08:00 , Mar 13, 2006 |  BC Week In Review  |  Clinical News

Recombinant Bet v 1 update

Data from the 3-year, double-blind, placebo-controlled, 4-arm, European DV08.01 trial in 150 patients showed significant improvement of rhino conjunctivitis symptoms in 3 active groups taking recombinant Bet v 1, commercially available birch pollen extract and...